Table 1 Baseline characteristics of study subjects
Characteristics | Study cohort (n = 191) |
|---|---|
Age (years): median (range) | 72 (34–88) |
Male gender: no. (%) | 149 (78) |
Cause of liver disease: no. (%) | |
HC | 112 (59) |
HB | 35 (18) |
HC + HB | 4 (2) |
Others | 40 (21) |
Child–Pugh class: no. (%) | |
A/B | 179/12 (94/6) |
ECOG PS: no. (%) | |
0 | 141 (74) |
1 | 47 (25) |
2 | 3 (1) |
BCLC stage: no. (%) | |
A | 11 (6) |
B | 85 (44) |
C | 95 (50) |
Prior treatment: no. (%) | |
Resection | 13 (7) |
Radio frequency ablation | 22 (11) |
Transarterial chemoembolization | 137 (72) |
None | 19 (10) |
Macroscopic vascular invasion: no. (%) | 51 (27) |
Extrahepatic spread: no. (%) | 56 (29) |
Reduced initiation dose: no. (%) | 65 (34) |
Laboratory data: median (range) | |
Hemoglobin (g/dL) | 12.5 (7.7–18.0) |
Platelet count (104/μ) | 12.3 (3.5–47.5) |
Aspartate aminotransferase (IU/L) | 55 (13–354) |
Alanine aminotransferase (IU/L) | 44 (10–238) |
Albumin (g/dL) | 3.7 (2.4–4.7) |
Total bilirubin (mg/dL) | 0.8 (0.3–2.6) |
AFP (ng/mL) | 81 (1.6–409,000) |
DCP (mAU/mL) | 332 (8–893,000) |